Psoriasis and Gut Microbiome—Current State of Art

Psoriasis is a chronic, immune-mediated inflammatory disease that affects around 125 million people worldwide. Several studies concerning the gut microbiota composition and its role in disease pathogenesis recently demonstrated significant alterations among psoriatic patients. Certain parameters such as Firmicutes/Bacteroidetes ratio or Psoriasis Microbiome Index were developed in order to distinguish between psoriatic and healthy individuals. The “leaky gut syndrome” and bacterial translocation is considered by some authors as a triggering factor for the onset of the disease, as it promotes chronic systemic inflammation. The alterations were also found to resemble those in inflammatory bowel diseases, obesity and certain cardiovascular diseases. Microbiota dysbiosis, depletion in SCFAs production, increased amount of produced TMAO, dysregulation of the pathways affecting the balance between lymphocytes populations seem to be the most significant findings concerning gut physiology in psoriatic patients. The gut microbiota may serve as a potential response-to-treatment biomarker in certain cases of biological treatment. Oral probiotics administration as well as fecal microbial transplantation were most reported in bringing health benefits to psoriatic patients. However, the issue of psoriatic bacterial gut composition, its role and healing potential needs further investigation. Here we reviewed the literature on the current state of the relationship between psoriasis and gut microbiome.     

Effect of gums on viability and β‐galactosidase activity of Lactobacillus spp. in milk drink during refrigerated storage

The viability and β‐galactosidase activity of four Lactobacillus strains in milk drink containing gums during 28 days of refrigerated storage at 4 °C were assessed. The population of Lactobacillus rhamnosus GGB101 and Lactobacillus rhamnosus GGB103 were maintained, whereas the population of Lactobacillus reuteri DSM20016 and Lactobacillus reuteri SD2112 significantly decreased. The recommended level of 6 log CFU g^?1 was exceeded for all tested trains throughout storage. The highest viable number of Lactobacillus rhamnosus GGB103 (8.76 ± 0.03 log CFU mL^?1) was obtained in the product containing carrageenan–maltodextrin. The addition of guar–locust bean–carrageenan led to 20‐fold increase in the level of β‐galactosidase activity for L. rhamnosus GGB101 (1208 ± 2.12 Miller units mL^?1) compared to the control (61 ± 2.83 Miller units mL^?1). Our results suggested that gums could be added to milk to improve viability and enhance β‐galactosidase activity of Lactobacillus.     

Emerging applications of nanotechnologies to probiotics and prebiotics

Fervid interests on nanoparticles are increasing within the scientific and non-scientific communities, as they are utilised in food and non-food applications. The versatility of emerging applications of nanoparticles makes them potentially harmful to the food, healthcare and environment sectors, and thus necessitates the development of nanonutraceuticals from nutritional substances such as antioxidants, vitamins, fatty acids, fibres, probiotics and prebiotics. This review excavated state of the art on nanotechnology applications such as gold and selenium particles, nanolayers, nanobeads, nanoemulsions and nanofibers to probiotics and prebiotics for the synthesis of anticancer, antimicrobial, antioxidant and photo-reactive products among others, and finally delved into other noteworthy considerations like safety. It is concluded that available literature on the current status of nanoprobiotics and prebiotics are exhaustive, despite their huge potentials and applications.     

The Gut Microbiota: A Potential Gateway to Improved Health Outcomes in Breast Cancer Treatment and Survivorship

Breast cancer is the most frequently diagnosed cancer in women worldwide. The disease and its treatments exert profound effects on an individual’s physical and mental health. There are many factors that impact an individual’s risk of developing breast cancer, their response to treatments, and their risk of recurrence. The community of microorganisms inhabiting the gastrointestinal tract, the gut microbiota, affects human health through metabolic, neural, and endocrine signaling, and immune activity. It is through these mechanisms that the gut microbiota appears to influence breast cancer risk, response to treatment, and recurrence. A disrupted gut microbiota or state of ‘dysbiosis’ can contribute to a biological environment associated with higher risk for cancer development as well as contribute to negative treatment side-effects. Many cancer treatments have been shown to shift the gut microbiota toward dysbiosis; however, the microbiota can also be positively manipulated through diet, prebiotic and probiotic supplementation, and exercise. The objective of this review is to provide an overview of the current understanding of the relationship between the gut microbiota and breast cancer and to highlight potential strategies for modulation of the gut microbiota that could lead to improved clinical outcomes and overall health in this population.     

乳化法制备两歧双歧杆菌微胶囊

以两歧双歧杆菌BB01和BB28为试验菌株,活茵数及包埋产率为指标,研究了海藻酸钠浓度、CaCI：浓度、乳化时间及固定化时间对乳化法制备两歧双歧杆菌微胶囊的影响．结果表明：当两歧双歧杆菌BB01微胶囊制备的条件分别为海藻酸钠浓度2％、CaCl2浓度1％、乳化时间10min、固定化时间15min时,对应的活菌数分别为4．9×10^9cfu／mL、3．06×10^9cfu／mL、2．47×10^9cfu／mL和4．37×10^9cfu／mL,包埋产率分别为80％、56．7％、40．9％和54．1％;当两歧双歧杆菌BB28微胶囊制备的条件分别为海藻酸钠浓度2．5oA、CaCl。浓度1％、乳化时间15min、固定化时间15min时,对应的活菌数分别为4．0×10^9cfu／mL、41×10^9cfu／mL、1．59×10^9cfu／mL和5．55×10^9cfu／mL,包埋产率分别为80％、92％、87％和76．1％．     

微生态制剂在水产养殖中的应用

主要从防治鱼病的发生及减少抗生素滥用、改良水质和防治有害蓝藻等三个方面的作用综述了微生物制剂在水产养殖中的应用现状及研究进展,分析了目前微生物制剂研究及生产中存在的问题,并对微生物制剂在水产养殖中的研究及应用发展趋势作了进一步的展望。     

Organic whey as a source of Lactobacillus strains with selected technological and antimicrobial properties

Twenty‐five strains, isolated from raw, non‐pasteurised, organic whey samples, were identified phenotypically and genotypically. Biochemical tests were performed, and enzyme profiles, antibiotic resistance and antimicrobial properties were investigated. Sixteen strains were identified as genus Lactobacillus. Based on 16S rDNA gene sequence, the strains were identified as Lb. plantarum and Lb. fermentum. All of the strains had β‐galactosidase activity, and some of them reduced nitrate content. All strains utilised carbohydrates. The tested strains were characterised by low or average lipolytic and esterolytic activity. Moreover, the strains showed low proteolytic activity which is advantageous for their use as starter cultures for foods with low protein content. Strains Lb. fermentum S20, SM1, SM3, S2R and Lb. plantarum SM5 produced harmful N‐acetyl‐β‐glucosaminidase; moreover, the strain S20 produced also β‐glucuronidase. None of the strains produced α‐chymotrypsin. In phenotypic studies, most of the test strains were susceptible to gentamicin, ampicillin, tetracycline, chloramphenicol, penicillin and erythromycin. Strains Lb. plantarum S1 and Lb. fermentum S4, S7, S8, S10, SM1 and SM3 did not possess any transfer resistance genes. Antagonistic activity of the culture LAB strains was assessed as high or moderate in relation to the indicator strains, with the greatest zones of inhibition for E.coli and the smallest for L. monocytogenes ATCC 15313. This study reveals that the LAB strains isolated from organic whey have high potential for food application. Some strains of species Lb. fermentum (S4, S7, S8, S10) have been identified as the best candidates.     

The effect of co-encapsulation of Lactobacillus rhamnosus GG ATCC 53103 with inulin on alginate/chitosan matrix: the viability in fermented soy blend and simulated digestive system

This research verified the ability of Lactobacillus rhamnosus encapsulated with inulin to tolerate the simulated digestive system and their viability in a soy blend. Probiotic encapsulated in alginate-chitosan matrix without inulin presented a better encapsulation efficiency (80.92%) than encapsulation with inulin (57.39%). On the 28th day, the count of probiotics decreased by 3.42 and 1.99 logarithmic cycles of free and encapsulated cells without inulin, respectively. In contrast, the microorganisms encapsulated with inulin showed an increase of 1.26 logs CFU g⁻¹. During gastrointestinal simulation, cell counts decreased by 0.78, 1.55 and 1.95 CFU g⁻¹ logs for encapsulated cells without inulin, free and encapsulated with inulin, respectively. Sensory panellists liked the fermented soy blend with encapsulated lactobacilli, and this result shows the possibility to create new probiotic foods of plant origin. Therefore, the alginate/chitosan matrix can be considered adequate for the encapsulation of L. rhamnosus. The inulin reduces the encapsulation efficiency and increases the cell loss in gastrointestinal simulation. Considering cellular losses, the best option for preparing a fermented soy blend is to use L. rhamnosus encapsulated without inulin.     

The Impact of the Microbiome on Resistance to Cancer Treatment with Chemotherapeutic Agents and Immunotherapy

Understanding the mechanisms of resistance to therapy in human cancer cells has become a multifaceted limiting factor to achieving optimal cures in cancer patients. Besides genetic and epigenetic alterations, enhanced DNA damage repair activity, deregulation of cell death, overexpression of transmembrane transporters, and complex interactions within the tumor microenvironment, other mechanisms of cancer treatment resistance have been recently proposed. In this review, we will summarize the preclinical and clinical studies highlighting the critical role of the microbiome in the efficacy of cancer treatment, concerning mainly chemotherapy and immunotherapy with immune checkpoint inhibitors. In addition to involvement in drug metabolism and immune surveillance, the production of microbiota-derived metabolites might represent the link between gut/intratumoral bacteria and response to anticancer therapies. Importantly, an emerging trend of using microbiota modulation by probiotics and fecal microbiota transplantation (FMT) to overcome cancer treatment resistance will be also discussed.     

猴头菇益生菌发酵对小鼠酒精性胃溃疡的保护作用

该实验采用保加利亚乳杆菌、嗜热链球菌、醋酸菌3种菌种发酵猴头菇,通过比较发酵液的DPPH自由基清除率,确定猴头菇发酵的最优条件。用猴头菇益生菌发酵液对酒精性胃溃疡模型的小鼠进行灌胃,测定胃溃疡小鼠胃组织中超氧化物歧化酶(SOD)、丙二醛(MDA)、过氧化氢酶(CAT)和血清中炎症因子白介素-6(IL-6)、白介素-10(IL-10)、肿瘤坏死因子-α(TNF-α)含量。结果表明,最佳发酵条件为起始p H值6.5、菌种复配比(保加利亚乳杆菌:嗜热链球菌:醋酸菌)1:1:1、接种量8.8%、发酵温度37.5℃、发酵时间27 h,发酵液菌落数为8.72×10⁹ CFU/mL、发酵液的DPPH自由基清除率可达79.59%。与模型组相比,高剂量组小鼠胃组织的SOD和CAT水平分别升高了71.38%和99.89%、MDA含量降低了47.45%;小鼠血清中的炎症因子TNF-α和IL-6含量分别降低了32.66%和34.95%、IL-10含量升高了100.46%,表明猴头菇益生菌发酵液对小鼠的急性酒精性胃溃疡有保护作用。该研究为猴头菇的应用提供了理论支持,为猴头菇新产品的开拓和益...